Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy as well as the safety of RAD001 in combination with
bevacizumab for recurrent ovarian, peritoneal, and fallopian tube cancer. RAD001 will be
taken orally once daily and bevacizumab will be administered once every 14 days. The study
will be conducted over a period of about 3 to 4 years.